Friday, September 26, 2008

Reckeweg Prices.doc

The first link on is to word document listing the "Hans-Heinrich Reckeweg Prizes." It's just a list of awards, giving fragments of the abstracts for the "research" that justified the award. The awards were awarded by "The International Society for Homotoxicology".

It's important to note that the "research" involves products manufactured and marketed by

The document gives no real numbers, just the grandiose claims of the researchers. Since I already have a lot of data to go over, I'm not going to go spelunking for studies for which very little data is given. If anyone has links to the studies below, please post them in the comments section.

From the document:
The first Hans-Heinrich Reckeweg Prize was awarded in 1995 to Professor Ryszard Matusiewicz, M.D., of the Department of Internal Medicine of Gorchowski Hospital, Warsaw. Dr. Matusiewicz conducted a double-blind, placebo-controlled study of 40 asthmatic patients, all of whom required corticosteroid therapy. In addition to their standard medication, some of the patients received Engystol N while others took a placebo. The Engystol group experienced improvements in pulmonary function and were able to reduce their corticosteroid dosages significantly.

No information on where the study may have been published was given.

In 1996 the prize was shared between two contestants. Dr. Karl-Heinz Ricken of Saarlouis received the award for successful use of a combination of antihomotoxic medications in treating not only digestive disorders but also Helicobacter pylori infections of the gastric mucosa. The other prizewinners, chemist and pharmacist Dr. Alessandro Orlandini of the University of Brescia (Italy) and his two coauthors, also demonstrated noteworthy achievement, clinically confirming the protective effect of Zeel on cartilage cells.

Again, no publication data was given.

No comments: